Live-Attenuated Vaccines in Pediatric Solid Organ Transplant

Area of Science:

• Pediatric infectious diseases
• Transplant immunology
• Vaccinology

Background:

• Childhood vaccination rates for MMR and varicella have declined due to COVID-19 pandemic-related delays.
• Reduced herd immunity poses risks to both immunocompetent children and immunocompromised individuals.
• Live-attenuated vaccines (MMR, varicella) were historically recommended pre-transplant, with timing and titer utility debated.

Purpose of the Study:

• To provide guidance on the use of live-attenuated vaccines (MMR and varicella) in pediatric solid organ transplant recipients.
• To review current literature on the safety and efficacy of these vaccines in the pre- and post-transplant settings.
• To address the risks and benefits of MMR and varicella vaccination in immunocompromised pediatric patients.

Main Methods:

• Literature review of studies on live-attenuated vaccines (MMR, varicella) in pediatric solid organ transplant patients.
• Analysis of safety and efficacy data from pre-transplant and post-operative phases.
• Synthesis of evidence to inform clinical practice guidelines.

Main Results:

• Recent literature suggests improved safety and efficacy profiles for live-attenuated vaccines in post-transplant pediatric populations.
• The optimal timing for pre-transplant vaccination and the role of vaccine titers warrant further investigation.
• Previously contraindicated vaccines may now be considered under specific circumstances.

Conclusions:

• Live-attenuated vaccines (MMR, varicella) may be safely administered to pediatric solid organ transplant recipients in certain pre- and post-transplant scenarios.
• Evidence supports a re-evaluation of vaccination strategies for immunocompromised children undergoing transplantation.
• Further research is needed to establish definitive protocols for vaccine administration and monitoring.